ASCENSIA DIABETES CARE ITALY - תוצאות חיפוש

cts chemical industries ltd, israel - ursodeoxycholic acid - טבליה - ursodeoxycholic acid 100 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reductin in size of radiolucent cholesterol in patient with a functioning gallbladder. treatment of chronic liver diseases including primary billiary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia, chronic hepatitis, and alcohol cirrhosis.

ישראל - עברית - Ministry of Health

אורסוליט 300

cts chemical industries ltd, israel - ursodeoxycholic acid - טבליה - ursodeoxycholic acid 300 mg - ursodeoxycholic acid - ursodeoxycholic acid - dissolution or reduction in size of radiolucent cholesterol gallstones in patients with a functioning gallbladder. treatment of chronic liver diseases including primary biliary cirrhosis, primary sclerosing cholangitis, cystic fibrosis associated liver disease, biliary atresia chronic hepatitis and alcoholic cirrhosis.

ישראל - עברית - Ministry of Health

בודסון 3 מג כמוסות

rafa laboratories ltd - budesonide - קפסולות - budesonide 3 mg - budesonide - budesonide - for the induction and maintenance of remission in patients with mild to moderate crohn's disease affecting the ileum and/or the ascending colon.

ישראל - עברית - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*